| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Glycitein is a soybean-derived O-methylated isoflavone aglycone. It exhibits weak estrogenic activity comparable to other soy isoflavones. Glycitein inhibits glioma cell invasion through down-regulation of MMP-3 and MMP-9 gene expression. It has antioxidant activity, increases Nrf2-related antioxidative signaling, destabilizes amyloid-β aggregates, prevents fibril assembly, and inhibits osteoclast generation.
|
|---|---|
| ln Vitro |
Glycitein (0-30 μM, 4 days/20 hours) suppresses the development and DNA synthesis of aortic smooth muscle cells (SMC) from stroke-prone spontaneous vessels (SHRSP) that are induced by glucose-coated charcoal/fetal bovine serum (DDC-FBS) [3]. Glycitein (100 μg/mL, 2 days) reduces Aβ-induced toxicity and induction in button nematodes Oxidation[6]. It also causes apoptosis, inhibits human cell viability, and promotes the G0/G1 phase.
In vitro, Glycitein has weak estrogenic activity. It shows antioxidant activity through DPPH radical scavenging with an IC50 value greater than 1000 nM. Glycitein inhibits glioma cell invasion through down-regulation of MMP-3 and MMP-9 gene expression. It increases Nrf2-related antioxidative signaling, destabilizes amyloid-β aggregates, and prevents fibril assembly. Its in vitro activity is characterized by estrogenic, antioxidant, and anti-invasive effects. |
| ln Vivo |
Daidzin (3 mg/day, oral gavage, 4 days) will raise the embryonic weight of weaned female B6D2F1 mice, despite its limited effect on female growth [1]. Soybean supplementation (15, 30, or 45 mg/kg) can improve the antioxidant index, lower the amount of MDA in sow yarn and milk, improve the composition of milk, and boost piglet growth in sows throughout the late pregnancy and fetal phase. performance [5].
In vivo, Glycitein has been studied for its potential health benefits related to its estrogenic, antioxidant, and anti-inflammatory activities. As a phytoestrogen, it may have effects on hormone-sensitive tissues. Glycitein inhibits osteoclast generation. However, detailed in vivo efficacy data for specific disease models are limited. Glycitein is primarily used as a research tool for studying isoflavone biology. |
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Glycitein typically involve measuring its binding to estrogen receptors. The compound has weak estrogenic activity. These assays confirm its mechanism of action as a phytoestrogen. Its antioxidant activity can also be assessed using DPPH radical scavenging assays.
|
| Cell Assay |
Cell viability assay [4]
Cell Types: human gastric cancer cells (AGS, MKN-28, 4]. MKN-45, NCI-N87, YCC-1, YCC-6, SNU-5, SNU-216, SNU-484, SNU-668) Tested Concentrations: 24 hrs (hours) Incubation Duration: 0-100 μM Experimental Results: IC50: 30.98, 60.17 are 35.07, 36.05, 33.11, 88.62, 97.68, 83.02, 46.87, 87.55 μM respectively. Apoptosis analysis [4] Cell Types: AGS Cell Tested Concentrations: 30 μM Incubation Duration: 3, 6, 12 and 24 hrs (hours) Experimental Results: Increased expression of Bax, Caspase-3 and cleaved PARP proteins and diminished Bcl-2 levels. Increase the fluorescence intensity of PI staining. In vitro cellular assays for Glycitein typically involve treating cancer cell lines such as glioma cells with the compound and measuring invasion, MMP-3 and MMP-9 expression, and Nrf2-related antioxidative signaling. Glycitein inhibits glioma cell invasion through down-regulation of MMP-3 and MMP-9 gene expression and increases Nrf2-related antioxidative signaling. These cell-based studies demonstrate its anti-invasive and antioxidant effects. |
| Animal Protocol |
In vivo animal models for Glycitein may include models of cancer, osteoporosis, or neurodegenerative diseases to evaluate its potential health benefits. However, detailed animal protocol information is limited. Glycitein is primarily used as a research tool for studying isoflavone biology and its effects on health.
|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
Glycine's known human metabolites include (2S,3S,4S,5R)-3,4,5-trihydroxy-6-[3-(4-hydroxyphenyl)-6-methoxy-4-oxochromen-7-yl]oxooxacyclohexane-2-carboxylic acid. Glycitein has a molecular weight of 284.26 and a molecular formula of C16H12O5. Its CAS number is 40957-83-3. The compound is a soybean isoflavonoid that accounts for 5-10% of the total isoflavones in soy food products. It has weak estrogenic activity and inhibits glioma cell invasion through down-regulation of MMP-3 and MMP-9. |
| Toxicity/Toxicokinetics |
Glycitein is a phytoestrogen with a well-characterized mechanism of action. As with any phytoestrogen, potential toxicity may include effects on hormone-sensitive tissues. The compound's safety profile should be evaluated in toxicological studies. Glycitein is for research use only and is not approved for human therapeutic use. It represents a valuable tool for studying isoflavone biology and health.
|
| References | |
| Additional Infomation |
Glycitein is a methoxyisoflavone with a structure in which the isoflavone is substituted with a methoxy group at the 6' position and with hydroxyl groups at the 7' and 4' positions. It has been isolated from the mycelium of Cordyceps sinensis. Glycitein functions as a plant metabolite, phytoestrogen, and fungal metabolite. It is a methoxyisoflavone and a 7-hydroxyisoflavone, functionally related to one of the isoflavones. Glycitein has been reported to be found in Spanish sage, soybean, and several other organisms with relevant data.
Glycitein (CAS# 40957-83-3) is a soybean isoflavonoid and phytoestrogen that accounts for 5-10% of total isoflavones in soy products. It has weak estrogenic activity, inhibits glioma cell invasion through down-regulation of MMP-3 and MMP-9, and has antioxidant activity. The compound is for research use only and not for human therapeutic use. |
| Molecular Formula |
C16H12O5
|
|---|---|
| Molecular Weight |
284.26
|
| Exact Mass |
284.068
|
| CAS # |
40957-83-3
|
| PubChem CID |
5317750
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
547.4±50.0 °C at 760 mmHg
|
| Melting Point |
>300ºC
|
| Flash Point |
210.1±23.6 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.669
|
| LogP |
2.57
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
21
|
| Complexity |
424
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
DXYUAIFZCFRPTH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H12O5/c1-20-15-6-11-14(7-13(15)18)21-8-12(16(11)19)9-2-4-10(17)5-3-9/h2-8,17-18H,1H3
|
| Chemical Name |
7-hydroxy-3-(4-hydroxyphenyl)-6-methoxychromen-4-one
|
| Synonyms |
Q100465; Q-100465; Glycitein
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~87.95 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (8.79 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.79 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5179 mL | 17.5895 mL | 35.1791 mL | |
| 5 mM | 0.7036 mL | 3.5179 mL | 7.0358 mL | |
| 10 mM | 0.3518 mL | 1.7590 mL | 3.5179 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
